CAR T-Cell Trials in DLBCL, FL Reflect Continued Promise
Updated results from the JULIET trial, testing tisagenlecleucel (Kymriah) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), revealed encouraging long term results.
News
ECHELON-2 Trial Demonstrates “Practice-Changing” Results for Peripheral T-Cell Lymphomas
ECHELON-2 is the first study in patients with PTCL to show an improvement in overall survival over a standard therapy such as CHOP
LRF Releases Monograph Addressing Early Career Scientist Crisis
In the face of declining federal and institutional resources, the Lymphoma Research Foundation’s (LRF) commitment to supporting early career lymphoma researchers has become more critical than ever before. To explore this important topic, the Foundation convened a Biden Cancer Community…
Former Pharmaceutical Executive Joins Lymphoma Research Foundation Board of Directors
Lymphoma Research Foundation Elects New Director Kim Metcalf to Impact Organization’s Strategic Growth New York (February 4, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma…
Foundation Releases 2019 Public Policy Agenda Outlining Policy Priorities For Year Ahead
The Lymphoma Research Foundation (LRF) is proud to be a national thought leader in the area of public policy, advocating for polices and legislation that will improve the lives of people with lymphoma and CLL. The Foundation leads efforts to…
FDA Approves Ibrutinib (IMBRUVICA) in Combination with Obinutuzumab (GAZYVA) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
New York, NY –The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) in combination with obinutuzumab (GAZYVA) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This…
U.S. Food and Drug Administration Approves Brentuximab Vedotin (ADCETRIS) for Frontline Treatment of Peripheral T-Cell Lymphoma (PTCL)
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has expanded the approved use of brentuximab vedotin (ADCETRIS) injection in combination with chemotherapy for adult patients with previously untreated systemic anaplastic large cell lymphoma (ALCL) and…
Foundation Hosts Biden Cancer Community Summit to Address Funding for Early Career Researchers
As part of the Lymphoma Research Foundation’s ongoing efforts in support of early career lymphoma researchers, the Foundation was proud to host a Biden Cancer Community Summit on September 21, 2018. The Summit, one of several held across the country…
In Memoriam: Paul Allen
The Lymphoma Research Foundation extends its heartfelt condolences to the family, loved ones and colleagues of Paul Allen. Mr. Allen contributed greatly to science, philanthropy and business and was committed to improving people’s lives and strengthening communities around the world. Our…
Lymphoma Research Foundation Annual Gala Raises More Than $2 Million to Advance Research and Patient Support Services
The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and support services – held its Annual Gala…